Bionik Laboratories Corp. announced that the Board of Directors has appointed Eric Dusseux, a director of the company since July 2017, as Chief Executive Officer, effective September 1, 2017. Dusseux is a proven executive who has spent the past 15 years focused on helping companies in the healthcare sector develop and execute strategic growth and commercialization plans.

Peter Bloch will continue to serve Bionik in the capacity as Chairman of the Board of Directors of the Company and will consult with the Company during the management transition. Peter Bloch, the Chief Executive Officer of the company, resigned as an officer of the company effective September 1, 2017. Mr. Bloch's departure is not related to any disagreement with the company's accounting or operating policies or practices.

In connection with this departure, the company and Mr. Bloch entered into a separation agreement, dated September 1, 2017. Effective September 1, 2017, Mr. Bloch commenced a new consulting position with the Company of EVP (Corporate Development and CFO) which shall continue until the later of (a) March 31, 2018 or (b) 3 months after a NASDAQ up-listing is completed if a NASDAQ up-listing is completed before March 31, 2018. On September 1, 2017, the Board increased the size of the Board from five to six members and appointed Remi Gaston Dreyfus to the Board effective as of September 1, 2017.